Payment overview · 2025
General Payments
$460.44
23 reported records · 14 companies
Healthcare provider profile · identity verified
Rachelle L Gorrell, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAINT JAMES, MO · NPI 1336114800
Verified facts
What the public records show
CMS Open Payments records show Rachelle L Gorrell, D.O. received $460.44 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Nurtec Odt, Ozempic, Rybelsus, Shingrix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $93.90 | 20.4% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.17 | 14.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.58 | 11.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $49.64 | 10.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $31.77 | 6.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.66 | 5.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $25.42 | 5.5% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.72 | 4.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $19.06 | 4.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.10 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.78 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.68 | 3.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $14.97 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.99 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $460.44 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.17 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.82 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $49.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.46 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.08 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25.42 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.54 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 75 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 28 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
74 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
65 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
28 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
116 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 762 | 139 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 547 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 518 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 451 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 428 | 101 |
| Famotidine | Famotidine | 419 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 416 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 98 |
| Lisinopril | Lisinopril | 394 | 87 |
| Gabapentin | Gabapentin | 371 | 78 |
| Omeprazole | Omeprazole | 371 | 76 |
| Trazodone Hcl | Trazodone Hcl | 335 | 58 |
| Montelukast Sodium | Montelukast Sodium | 324 | 63 |
| Metformin Hcl Er | Metformin Hcl | 316 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 298 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 294 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 62 |
| Losartan Potassium | Losartan Potassium | 289 | 70 |
| Potassium Chloride | Potassium Chloride | 285 | 68 |
| Furosemide | Furosemide | 281 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 243 | 42 |
| Buspirone Hcl | Buspirone Hcl | 223 | 45 |
| Alprazolam | Alprazolam | 222 | 43 |
| Jardiance | Empagliflozin | 210 | 41 |
| Pregabalin | Pregabalin | 204 | 45 |
| Tramadol Hcl | Tramadol Hcl | 198 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 196 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 190 | 35 |
| Glimepiride | Glimepiride | 184 | 28 |
| Metformin Hcl | Metformin Hcl | 183 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 158 | 44 |
| Morphine Sulfate Er | Morphine Sulfate | 157 | 19 |
| Meloxicam | Meloxicam | 155 | 37 |
| Prednisone | Prednisone | 154 | 76 |
| Sertraline Hcl | Sertraline Hcl | 147 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 146 | 34 |
| Simvastatin | Simvastatin | 140 | 31 |
| Baclofen | Baclofen | 134 | 25 |
| Mounjaro | Tirzepatide | 132 | 16 |
| Carvedilol | Carvedilol | 127 | 29 |
| Celecoxib | Celecoxib | 117 | 27 |
| Liothyronine Sodium | Liothyronine Sodium | 117 | 20 |
| Eliquis | Apixaban | 116 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 34 |
| Spironolactone | Spironolactone | 110 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 108 | 25 |
| Allopurinol | Allopurinol | 106 | 22 |
| Ibuprofen | Ibuprofen | 106 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 102 | 26 |
| Ozempic | Semaglutide | 102 | 24 |
| Lorazepam | Lorazepam | 100 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 91 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 90 | 13 |
| Finasteride | Finasteride | 88 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 84 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 84 | 19 |
| Clonazepam | Clonazepam | 83 | 17 |
| Januvia | Sitagliptin Phosphate | 79 | 12 |
| Synthroid | Levothyroxine Sodium | 79 | 19 |
| Ezetimibe | Ezetimibe | 75 | 16 |
| Farxiga | Dapagliflozin Propanediol | 75 | 12 |
| Linzess | Linaclotide | 74 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 13 |
| Sucralfate | Sucralfate | 72 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 71 | 22 |
| Fenofibrate | Fenofibrate | 69 | suppressed |
| Myrbetriq | Mirabegron | 68 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 16 |
| Bupropion Xl | Bupropion Hcl | 67 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 64 | 12 |
| Memantine Hcl | Memantine Hcl | 64 | 12 |
| Alendronate Sodium | Alendronate Sodium | 63 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | suppressed |
| Diazepam | Diazepam | 60 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | suppressed |
| Vascepa | Icosapent Ethyl | 59 | suppressed |
| Ondansetron Odt | Ondansetron | 58 | 14 |
| Propranolol Hcl | Propranolol Hcl | 58 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | suppressed |
| Trulicity | Dulaglutide | 54 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 11 |
| Xarelto | Rivaroxaban | 53 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 52 | 43 |
| Lamotrigine | Lamotrigine | 52 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 47 | 37 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 46 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 46 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 45 | 13 |
| Fluconazole | Fluconazole | 44 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 11 |
| Glipizide | Glipizide | 43 | 12 |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 39 | suppressed |
| Valsartan | Valsartan | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 33 |
| Irbesartan | Irbesartan | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 23 |
| Cefdinir | Cefdinir | 37 | 34 |
| Acyclovir | Acyclovir | 36 | suppressed |
| Estradiol | Estradiol | 36 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 36 | suppressed |
| Nystatin | Nystatin | 36 | 18 |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Cartia Xt | Diltiazem Hcl | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Lubiprostone | Lubiprostone | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 23 |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 27 | 13 |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Meropenem | Meropenem | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 15 |
| Olanzapine | Olanzapine | 27 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 21 |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 18 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| M-Natal Plus | Pnv,calcium 72/Iron/Folic Acid | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 15 |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Ursodiol | Ursodiol | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 14 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Modafinil | Modafinil | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Ramelteon | Ramelteon | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $460.44 · 23 records | ABBVIE INC. | Auvelity, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE, IBSRELA, MONOFERRIC, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error